CurrentBlue Cross Blue Shield - OklahomaPolicy CPCPLABO4S

Pathogen Panel Testing

This policy governs outpatient reimbursement criteria for multiplex and molecular pathogen panel testing and affects providers submitting claims to Blue Cross Blue Shield of Oklahoma.

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyPathogen Panel Testing

Policy CodePolicy CPCPLABO4S

Change TypeCodes addedclarification of outpatient scope and non-reimbursable panel types

Effective DateAug 1, 2025

Next Review Date

Key ActionProviders must submit accurate documentation and use valid HIPAA-approved code combinations; claims may require additional documentation upon request.

SourceLink

POLICY UPDATE CHANGES

Added codes 0590U and 0593U effective 10/01/2025.

Added codes 0202U, 0223U, 0225U, and 0531U.

Added CPT code 0528U effective 01/01/2025.

Policy is specific to testing in the outpatient setting.

Reimbursement Information updated to specify which panel types are not reimbursable (e.g., panels of 6+ respiratory pathogens, CSF, blood, urine UTI panels, wound panels, general screening panels).

7distinct non-reimbursable panel categories listed

25+procedure codes listed in policy

outpatient onlysetting restriction

2.0policy version

08/01/2025latest approval date

Outpatient Pathogen Panel Coverage Criteria

Outpatient pathogen panel coverage criteria

Outpatient reimbursement criteria and non-reimbursable categories:

Multiplex PCR-based panel testing (up to 5 respiratory pathogens) may be reimbursable for individuals who are displaying signs and symptoms of a respiratory tract infection, including at least one of the following: pronounced dyspnea; temperature >= 1029 F (as written in source); tachypnea; or tachycardia.

Multiplex PCR-based panel testing of 6 or more respiratory pathogens is not reimbursable.

Multiplex PCR-based panel testing of pathogens in cerebrospinal fluid (CSF) is not reimbursable.

Molecular detection-based panel testing of pathogens in the blood is not reimbursable.

Molecular detection-based panel testing of urine pathogens for the diagnosis of urinary tract infections (example: GENETWORx Molecular PCR UTI Test) is not reimbursable.

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyPathogen Panel Testing

Policy CodePolicy CPCPLABO4S

Change TypeCodes addedclarification of outpatient scope and non-reimbursable panel types

Effective DateAug 1, 2025

Next Review Date

Key ActionProviders must submit accurate documentation and use valid HIPAA-approved code combinations; claims may require additional documentation upon request.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Documentation, Claim Submission, and Billing Requirements

Documentation Required

Documentation, coding and claim-submission requirements

Providers are responsible for submitting accurate documentation of services performed and must submit claims using valid HIPAA-approved code combinations and industry-standard coding guidelines. Claims are subject to code edit protocols and claim review (including benefit terms, provider contract language, medical and coding policies, and coding software logic); additional documentation may be requested and should be provided upon request.

Submit claims using valid code combinations from HIPAA‑approved code sets and follow industry standard coding guidelines (e.g., UB Editor, AMA CPT, HCPCS, ICD‑10, NDC, DRG, CMS NCCI).
Be prepared for claims to be reviewed under code edit protocols and to supply additional documentation when requested.

Key Definitions

Multiplex PCR-based panel testing (respiratory)

DefinitionMultiplex PCR-based panel testing (respiratory) refers to molecular assays that detect multiple respiratory pathogen targets simultaneously using PCR-based methods.

Scope - reimbursable usePanels that include up to 5 respiratory pathogen targets may be reimbursable when used for individuals displaying signs and symptoms of a respiratory tract infection (see required clinical signs).

Scope - non-reimbursable useMultiplex PCR-based panel testing of 6 or more respiratory pathogens is explicitly not reimbursable under this policy.

Outpatient testing

ApplicabilityThis policy is specific to testing in the outpatient setting; criteria do not apply to testing in other than the outpatient setting.

Scope limitationReimbursement rules and non-reimbursable panel categories listed in the policy apply only when testing is performed in outpatient settings.

Exclusion for other settingsTests performed in inpatient or non-outpatient settings are not governed by the criteria in this policy.

87154
87483
87631
87632
87633
87636
87637
0068U
0086U
0109U

OpenPayer

Pathogen Panel Testing

Outpatient Pathogen Panel Coverage Criteria

Procedure Codes and Coding Rules

Documentation, Claim Submission, and Billing Requirements

Key Definitions